Rachel C Jankowitz
Affiliation: University of Pittsburgh
- Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-termRachel C Jankowitz
University of Pittsburgh Cancer Institute, Magee Women s Hospital, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
Breast Cancer Res 14:308. 2012..Ongoing study is needed to identify markers of resistance to trastuzumab and incorporate newer agents in the adjuvant setting in order to further decrease rates of distant recurrence and death from HER2-positive breast cancer...
- Epigenetics in breast cancer: what's new?Yi Huang
University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA 15232, USA
Breast Cancer Res 13:225. 2011....
- Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancerRachel C Jankowitz
Department of Medicine, Division of Hematology Oncology, UPMC, University of Pittsburgh Cancer Institute, 300 Halket Street, Suite 4628, Pittsburgh, PA 15213, USA
Breast Cancer Res 13:R98. 2011..Objectives of the current study were to validate BCI in a clinical case series and to compare the prognostic utility of BCI and Adjuvant!Online (AO)...